Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
May 19 2022 - 4:05PM
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology
company focused on developing advanced therapies for autoimmune and
inflammatory diseases, presented results from the CASCADE and
CORONET studies in patients with COVID-19 pneumonia at the American
Thoracic Society (ATS) 2022 Annual Meeting.
CASCADE, an observational study in a single United Kingdom
hospital, explored relationships between circulating biomarkers and
risk stratification categories in subsets of COVID-19 pneumonia
patients. Patients were clinically stratified as mild, moderate or
severe according to degree of respiratory failure on admission and
compared to matched healthy controls. Several biomarkers of
inflammation, including complement, were elevated across all
patient groups compared to healthy controls with complement C5a
higher in severe patients compared to moderate patients.
The CORONET study evaluated compassionate use of investigational
nomacopan in the treatment of hospitalized COVID-19 pneumonia
patients at two centers in the United States. As seen in CASCADE
and other studies, the innate immune system plays a potentially
important role in driving the pathology of COVID-19 pneumonia.
Nomacopan inhibits complement C5a and leukotriene B4 (LTB4). Seven
patients were treated with a 45mg subcutaneous dose of nomacopan
twice (every 12 hours) on the first day. Subsequently, patients
were administered 45mg of subcutaneous nomacopan once daily for 12
days. Prophylactic antibiotics were co-administered with nomacopan.
Six patients who received the full course of treatment with
nomacopan in the CORONET study survived and were discharged from
the hospital. One patient who experienced a delay in the initiation
of treatment died. No treatment-related adverse effects were
observed.
The posters are available at
http://investor.akaritx.com/news-and-events/presentations.
About Akari TherapeuticsAkari Therapeutics, plc
(Nasdaq: AKTX) is a biotechnology company focused on developing
advanced therapies for autoimmune and inflammatory diseases.
Akari's lead asset, investigational nomacopan, is a bispecific
recombinant inhibitor of C5 complement activation and leukotriene
B4 (LTB4) activity. The Akari pipeline includes two late-stage
programs for bullous pemphigoid (BP) and thrombotic microangiopathy
(TMA), as well as earlier stage research and development programs
in eye and lung diseases with significant unmet need. For more
information about Akari, please visit akaritx.com.
Cautionary Note Regarding Forward-Looking
StatementsCertain statements in this press release
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-
looking statements reflect our current views about our plans,
intentions, expectations, strategies and prospects, which are based
on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions,
expectations, strategies and prospects as reflected in or suggested
by those forward- looking statements are reasonable, we can give no
assurance that the plans, intentions, expectations or strategies
will be attained or achieved. Furthermore, actual results may
differ materially from those described in the forward-looking
statements and will be affected by a variety of risks and factors
that are beyond our control. Such risks and uncertainties for our
company include, but are not limited to: needs for additional
capital to fund our operations, our ability to continue as a going
concern; uncertainties of cash flows and inability to meet working
capital needs; an inability or delay in obtaining required
regulatory approvals for nomacopan and any other product
candidates, which may result in unexpected cost expenditures; our
ability to obtain orphan drug designation in additional
indications; risks inherent in drug development in general;
uncertainties in obtaining successful clinical results for
nomacopan and any other product candidates and unexpected costs
that may result there; difficulties enrolling patients in our
clinical trials; failure to realize any value of nomacopan and any
other product candidates developed and being developed in light of
inherent risks and difficulties involved in successfully bringing
product candidates to market; inability to develop new product
candidates and support existing product candidates; the approval by
the FDA and EMA and any other similar foreign regulatory
authorities of other competing or superior products brought to
market; risks resulting from unforeseen side effects; risk that the
market for nomacopan may not be as large as expected risks
associated with the impact of the COVID-19 pandemic; inability to
obtain, maintain and enforce patents and other intellectual
property rights or the unexpected costs associated with such
enforcement or litigation; inability to obtain and maintain
commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our
active pharmaceutical ingredients from third party manufacturers on
whom the company depends; unexpected cost increases and pricing
pressures and risks and other risk factors detailed in our public
filings with the U.S. Securities and Exchange Commission, including
our most recently filed Annual Report on Form 20-F filed with the
SEC. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no
obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release.
For more information
Investor Contact:Peter VozzoICR Westwicke(443)
213-0505peter.vozzo@westwicke.com
Media Contact:Sukaina Virji/ Maya BennisonConsilium Strategic
CommunicationsAkari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024